Overview

A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome

Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome
Phase:
Phase 2
Details
Lead Sponsor:
Aardvark Therapeutics, Inc.
Collaborator:
Children's Hospital Colorado